Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention

BACKGROUND: Casirivimab and imdevimab (REGEN-COV™) markedly reduces risk of hospitalization or death in high-risk individuals with Covid-19. Here we explore the possibility that subcutaneous REGEN-COV prevents SARS-CoV-2 infection and subsequent Covid-19 in individuals at high risk of contracting SA...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Brien, Meagan P., Forleo-Neto, Eduardo, Musser, Bret J., Isa, Flonza, Chan, Kuo-Chen, Sarkar, Neena, Bar, Katharine J., Barnabas, Ruanne V., Barouch, Dan H., Cohen, Myron S., Hurt, Christopher B., Burwen, Dale R., Marovich, Mary A., Hou, Peijie, Heirman, Ingeborg, Davis, John D., Turner, Kenneth C., Ramesh, Divya, Mahmood, Adnan, Hooper, Andrea T., Hamilton, Jennifer D., Kim, Yunji, Purcell, Lisa A., Baum, Alina, Kyratsous, Christos A., Krainson, James, Perez-Perez, Richard, Mohseni, Rizwana, Kowal, Bari, DiCioccio, A. Thomas, Stahl, Neil, Lipsich, Leah, Braunstein, Ned, Herman, Gary, Yancopoulos, George D., Weinreich, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219114/
https://www.ncbi.nlm.nih.gov/pubmed/34159344
http://dx.doi.org/10.1101/2021.06.14.21258567

Ejemplares similares

Ejemplares similares